Biosimilar Prescribing Incentives: Results of a French Pilot of Gainsharing Between Hospitals and the National Health Insurance

Vincent Attia, Mathilde Gaini, Edouard Maugendre and Catherine Pollak

Economie et Statistique / Economics and Statistics, 2024, issue 542, 147-168

Abstract: [eng] This article evaluates an incentive for hospital prescriptions of biosimilars delivered in retail pharmacies, whereby gains are shared between hospitals and the French NHI and incentives are directly redirected to prescribing units. Using SNDS data, we compare the pre- and post- biosimilar prescription rates of treated public hospitals with those observed at similar facilities. Between October 2018 and September 2021, the pilot led to an increase in biosimilar use for insulin glargine (+6.0 percentage points) and etanercept (+10.8 ppt). The pilot generated 0.5% cost savings for insulin glargine and 0.1% for etanercept. Cost savings for the French NHI are modest even though the incentive dramatically boosted biosimilar use. The fact that medication price changes outpaced the rate at which incentives are adjusted is the primary reason for this, in addition to deadweight loss effects.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.insee.fr/en/statistiques/fichier/8186110/08_ES542_Attia_et-al_EN.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nse:ecosta:ecostat_2024_542_8

DOI: 10.24187/ecostat.2024.542.2115

Access Statistics for this article

Economie et Statistique / Economics and Statistics is currently edited by Dominique Goux

More articles in Economie et Statistique / Economics and Statistics from Institut National de la Statistique et des Etudes Economiques (INSEE) Contact information at EDIRC.
Bibliographic data for series maintained by Veronique Egloff ().